ArticlePharmaceuticals (Basel, Switzerland)2025

Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors.

Zhijie Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.